About Spherotec
Spherotec uses three-dimensional cell culture systems that have similar characteristics to the microtumors of cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies realistic functional testing of drug candidates for oncology. In this way, promising substances can be identified at an early stage.
This so-called spheroid technology provides a comprehensive profile of substances. It can be used in all phases of drug development. The method can also be used to define the tumor type for which a substance or combination of substances has the best clinical efficacy.
Spherotec was founded in 2006 as a spin-off from the Ludwig Maximillians University of Munich. The founders are PD Dr. rer. hum. biol. Barbara Mayer and PD Dr. med. Ilona Funke.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
